ESC 365 - RE-CIRCUIT and reversal: how will our practice change?

EHRA Premium Access

RE-CIRCUIT and reversal: how will our practice change?

Session: RE-CIRCUIT: uninterrupted dabigatran as a new strategy in atrial fibrillation ablation

Topic: Atrial fibrillation ablation

Speaker: Doctor H. Calkins (Baltimore, US)

Sponsored by Boehringer Ingelheim

Event: EHRA EUROPACE - CARDIOSTIM 2017

Congress Presentation

Add to my library

About the speaker

Doctor Hugh Calkins

The Johns Hopkins Hospital, Baltimore (United States of America)

18 presentations

1 follower

3 more presentations in this session

Anticoagulation care in the electrophysiology lab: what do we know so far?

Speaker: Professor G. Lip (Liverpool, GB)

New evidence on periprocedural strategies for atrial fibrillation ablation: the RE-CIRCUIT trial.

Speaker: Professor S. Willems (Hamburg, DE)

Audience Q&A.

Speaker: Professor G. Lip (Liverpool, GB)

Access the full session

RE-CIRCUIT: uninterrupted dabigatran as a new strategy in atrial fibrillation ablation

Speakers: Doctor H. Calkins, Professor G. Lip, Professor S. Willems, Professor G. Lip

About the event

EHRA EUROPACE - CARDIOSTIM 2017

18 June - 21 June 2017

Sessions Presentations

Congress

ESC 365 is supported by

bristol-myers-squibb

Explore sponsored resources

novartis

Explore sponsored resources